Shared Audit Response

Pharma Third-Party Shared Audits (Rephine/Qualifyze) Response & Remediation Guide

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Introducing GxP shared audit models by Rephine and Qualifyze, mapping checklists (EU GMP Part II), common critical findings, and CAPA closure.

Key answer

Rephine, Qualifyze, and Rx-360 conduct GxP shared audits on API/excipient sites globally, aligned with ICH Q7 / EU GMP Part II. The audit report is added to their registry for drug manufacturers to license. Readiness work should address cleanroom smoke studies, computerized data integrity, and cross-contamination prevention.

Typical Finding Areas in Shared Audits

Historical data shows third-party auditors dive deeper into system integrity compared to standard buyers. Critical/Major findings are often associated with the following areas.

  • Cleaning Validation: failing to evaluate residue limits using ADE/PDE for the most active compounds
  • Data Integrity: audit trails disabled on HPLC software or lacking documented review records
  • HVAC & Water: uncalibrated dust sensors, or pressure differential logs missing verification signatures

FAQ

How long is a shared audit report valid?+

A shared audit report is typically valid for 3 years. When a pharma buyer sources from you, they license the report directly. If findings exist, the buyer requires the site to submit a CAPA tracker and closure evidence.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.